| Literature DB >> 32700163 |
Bastian Niklas Hölzel1,2, Kurt Pfannkuche3, Bernhard Allner4, Hans Thomas Allner4, Jürgen Hescheler5, Daniel Derichsweiler5, Henner Hollert6,7, Andreas Schiwy6,7, Julia Brendt8, Michael Schaffeld9, Alexander Froschauer10, Petra Stahlschmidt-Allner11.
Abstract
In vitro assessment of genotoxicity as an early warning tool for carcinogenicity mainly relies on recording cytogenetic damages (micronuclei, nucleoplasmic bridges) in tumour-derived mammalian cell lines like V79 or CHO. The forecasting power of the corresponding standardised test is based on epidemiological evidence between micronuclei frequencies and cancer incidence. As an alternative to destructive staining of nuclear structures a fish stem cell line transgenic for a fusion protein of histone 2B (H2B) and enhanced green fluorescent protein (eGFP) was established. The cells are derived from koi carp brain (KCB) and distinguish from mammalian culturable cells by non-tumour-driven self-renewal. This technology enables the analysis of genotoxic- and malign downstream effects in situ in a combined approach. In proof-of concept-experiments, we used known carcinogens (4-Nitroquinoline 1-oxide, colchicine, diethylstilbestrol, ethyl methanesulfonate) and observed a significant increase in micronuclei (MNi) frequencies in a dose-dependent manner. The concentration ranges for MNi induction were comparable to human/mammalian cells (i.e. VH-16, CHL and HepG2). Cannabidiol caused the same specific cytogenetic damage pattern as observed in human cells, in particular nucleoplasmic bridges. Metabolic activation of aflatoxin B1 and cyclophosphamide could be demonstrated by pre-incubation of the test compounds using either conventional rat derived S9 mix as well as an in vitro generated biotechnological alternative product ewoS9R. The presented high throughput live H2B-eGFP imaging technology using non-transformed stem cells opens new perspectives in the field of in vitro toxicology. The technology offers experimental access to investigate the effects of carcinogens on cell cycle control, gene expression pattern and motility in the course of malign transformation. The new technology enables the definition of Adverse Outcome Pathways leading to malign cell transformation and contributes to the replacement of animal testing. Summary: Complementation of genotoxicity testing by addressing initiating events leading to malign transformation is suggested. A vertebrate cell model showing "healthy" stemness is recommended, in contrast to malign transformed cells used in toxicology/oncocology.Entities:
Keywords: AOP for malign transformation; Micronucleus test; Non-destructive live-cell imaging technology
Mesh:
Substances:
Year: 2020 PMID: 32700163 PMCID: PMC7415759 DOI: 10.1007/s00204-020-02821-3
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Fig. 3Pooled micronucleus frequencies of different wells/experiments of cells treated with different concentrations of DMSO, CBD, 4-NQO, EMS, Colchicine, DES, AFB1 and CP (AFB1 and CP both metabolic activated by animal S9 mix and a biotechnological ewoS9R enzyme mix) after 24 h treatment and additional 24 h recovery (3 h treatment and 45 h of recovery for AFB1 and CP) with the corresponding negative control for each compound. *p < 0.05 vs control; **p < 0.001 vs control
Shows The cumulated micronucleus frequencies of each concentration of the test compounds as well as the negative control after 24 h of treatment and 24 h of recovery (3 h of treatment and 45 h of recovery for clastogens that require metabolic activation), the total number of cells assessed and the statistical results including the p-values and functions
| Compound | Concentration | Number of cells | Mean micronucleus frequency | |
|---|---|---|---|---|
4-Nitroquinoline | Control | 39,098 | 0.679 | |
| 0.025 µM | 7647 | 1.364 | ||
| 0.05 µM | 24,734 | 1.708 | ||
| 0.1 µM | 23,654 | 2.247 | ||
| 0.2 µM | 17,439 | 7.500 | R | |
| 0.3 µM* | 2654 | 9.910 | ||
Ethyl methanesulfonate | Control | 12,905 | 0.415 | |
| 1.28 mM | 13,367 | 0.439 | ||
| 2.56 mM | 15,157 | 0.320 | ||
| 3.84 mM | 11,395 | 0.733 | ||
| 5.12 mM | 8533 | 1.048 | ||
Colchicine | Control | 29,834 | 0.778 | |
| 0.031 µM | 25,320 | 0.847 | ||
| 0.062 µM | 23,577 | 1.464 | ||
| 0.125 µM | 12,936 | 2.200 | ||
| 0.188 µM* | 11,894 | 2.032 | ||
Diethylstilbestrol | Control | 18,969 | 0.483 | |
| 15 µM | 7399 | 0.416 | ||
| 30 µM | 15,238 | 0.746 | ||
| 45 µM | 6310 | 0.636 | ||
| 60 µM | 11,340 | 1.011 | ||
| 90 µM* | 5796 | 2.469 | ||
| 120 µM* | 2175 | 4.202 | ||
Aflatoxin B1 + ewoS9R | Control | 3449 | 0.377 | |
| 0.00625 mM | 4030 | 0.596 | ||
| 0.0125 mM | 4187 | 0.549 | ||
| 0.025 mM | 3244 | 0.956 | ||
| 0.05 mM | 2840 | 0.915 | ||
| 0.1 mM | 3491 | 0.802 | ||
| 0.2 mM | 2307 | 1.517 | ||
| 0.4 mM | 2062 | 2.279 | ||
| 0.8 mM | 1293 | 3.326 | ||
| 1.6 mM | 793 | 3.531 | ||
Aflatoxin B1 + S9 mix | Control | 5550 | 0.631 | |
| 0.00625 mM | 4290 | 0.583 | ||
| 0.0125 mM | 3495 | 1.059 | ||
| 0.025 mM | 3346 | 0.837 | ||
| 0.05 mM | 4395 | 0.865 | ||
| 0.1 mM | 2673 | 1.085 | ||
| 0.2 mM | 3263 | 1.502 | ||
| 0.4 mM | 2237 | 2.414 | ||
| 0.8 mM | 2281 | 3.595 | ||
| 1.6 mM | 2367 | 3.718 | ||
Cyclophosphamide + ewoS9R | Control | 4046 | 0.420 | |
| 1.132 µM | 3702 | 0.594 | ||
| 2.266 µM | 3644 | 0.302 | ||
| 4.531 µM | 2570 | 0.817 | ||
| 9.063 µM | 3307 | 0.605 | ||
| 18.125 µM | 2340 | 0.812 | ||
| 36.25 µM | 2871 | 1.219 | ||
| 72.5 µM | 2156 | 1.855 | ||
| 145 µM | 3477 | 1.179 | ||
| 290 µM | 3008 | 1.496 | ||
Cyclophosphamide + S9 mix y = 0.8913 + 0.0188x− 3.2630E-005 | Control | 2747 | 0.837 | |
| 1.132 µM | 3080 | 0.812 | ||
| 2.266 µM | 2494 | 1.002 | ||
| 4.531 µM | 2333 | 0.986 | ||
| 9.063 µM | 2486 | 1.046 | ||
| 18.125 µM | 2560 | 1.289 | ||
| 36.25 µM | 2169 | 1.245 | ||
| 72.5 µM | 2144 | 1.726 | ||
| 145 µM | 2397 | 2.545 | ||
| 290 µM | 2111 | 3.316 | ||
DMSO | Control | 15,961 | 0.407 | |
| 0.25% | 12,772 | 0.469 | ||
| 0.5% | 13,704 | 0.492 | ||
| 1.0% | 10,067 | 0.559 | ||
| 2.0%* | 8981 | 0.746 | ||
Cannabidiol | Control | 10,080 | 0.387 | |
| 0.159 µM | 11,512 | 0.487 | ||
| 0.318 µM | 10,423 | 0.441 | ||
| 1.590 µM | 9392 | 0.532 | ||
| 3.180 µM | 8857 | 0.700 |
*Cytotoxicity threshold concentrations not tested repeatedly
Fig. 1Nuclear structure of fixed cells with nuclei in interphase (a), during anaphase (b), during metaphase with difficulties to align properly (c), during anaphase with lagging chromosomes (d), as a main nucleus with a micronucleus beside (e), as a fragmented nucleus (f), as an elongated nucleus (g) and as a motile, elongated nucleus with a micronucleus beside (h). Pictures were taken in unexposed cultures (a, b), in colchicine exposed cultures (c, d), in 4-NQO exposed cultures (e, f) and in cannabidiol exposed cultures (g, h). Scale bar: 10 µm
Fig. 2Nuclear structures of fixed cells after cannabidiol exposure. Solid nucleoplasmic bridges as a result of incomplete nuclear divisions (a, b). Filigree extrusion of nuclear material as a result of mechanical stress in the course of nuclear transport in cellular tubes (c). Filigree long-distance nucleoplasmic bridges of unknown genesis (d, e). Scale bar: 10 µm
Fig. 4a Micronuclei induction by 4-NQO, colchicine, DES and EMS in KCB H2B-eGFP cells with varying exposure and recovery treatments. Micronucleus frequencies were assessed either after 12 h (12 + 0 h) or 24 h (24 + 0 h) of treatment and after 24 h of treatment with additional 24 h of recovery (24 + 24 h). b Solid nucleoplasmic bridges and MNi Frequencies observed at different time points of the same cannabidiol exposure experiment
Frequencies of spontaneously occurring micronuclei observed to date in different cell lines
| Cell line | MNi frequencies (%) |
|---|---|
| KCB | 0.58 |
| V79 (Chinese hamster lung cell line) (Ellard and Parry | 0.86 or 0.9 ± 0.3* |
| CHL (Chinese hamster lung cell line) (Matsushima et al. | 0.91* or 1.6 or 0.70 |
| HepG2 (Human liver cancer cell line) (Valentin-Severin et al. | 1* |
| VH-16 (Primary human foreskin fibroblast) (Antoccia et al. | 1.17 and 1.3* |
| HeLa (Human cervical cancer cell line) (Rao et al. | 4.72 |
| SHE (Syrian hamster embryo fibroblasts) (Schmuck et al. | 0.72 ± 0.215 |
For the determination of MNi frequencies highlighted with (*), the cells were treated with cytochalasin B